PHASE 2 STUDY OF COMBIDEX IN AUXILIARY NODE STAGING IN BREAST CANCER

本子项目是利用由NIH/NCRR资助的中心赠款提供的资源的众多研究子项目之一。子项目和研究者（PI）可能已经从另一个NIH来源获得了主要资金，因此可以在其他CRISP条目中表示。列出的机构是中心的，不一定是研究者的机构。本研究的主要目的是评估Combidex磁共振成像在确定和定位转移性乳腺癌淋巴结累及方面的初步疗效。大量的临床前和临床研究表明，Combidex可以高特异性地识别癌症累及的淋巴结。本研究将进一步评估Combidex MR正确识别和定位转移性乳腺癌腋窝淋巴结累及的能力。希望使用Combidex对淋巴结进行磁共振成像，将成为一种比目前可用的方法更有效的乳腺癌相关淋巴结疾病成像方法。该研究的次要目的是确定复方碧德如何改变原发性乳腺肿瘤的磁共振成像表现。大约30-50名患者将从这个医疗中心参加这项研究。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The primary objective of this study is to assess the preliminary efficacy of Combidex MR imaging in defining and localizing nodal involvement by metastatic breast cancer. Numerous pre-clinical and clinical studies demonstrate that Combidex can identify cancer-involved lymph nodes with high specificity. This study will further evaluate the ability of Combidex MR to correctly identify and localize axillary nodal involvement by metastatic breast cancer. It is hoped that MR imaging of lymph nodes with Combidex will be a more effective procedure for imaging lymph node disease associated with breast cancer than the procedures that are currently available. The secondary objective of the study is to determine how Combidex changes the MR imaging appearance of primary breast tumors. About 30-50 patients will take part in this study from this medical center.